Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties

被引:70
作者
Cruess, Alan F. [1 ]
Zlateva, Gergana [2 ]
Pleil, Andreas M. [3 ]
Wirostko, Barbara [2 ]
机构
[1] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada
[2] Pfizer Ophthalm, New York, NY USA
[3] Pfizer World Wide Outcomes Res, La Jolla, CA USA
关键词
age-related macular degeneration; choroidal neovascularization; photodynamic therapy; verteporfin; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL TRIAMCINOLONE; COST-EFFECTIVENESS; VISUAL IMPAIRMENT; PEGAPTANIB SODIUM; RETINAL FUNCTION; TRIPLE THERAPY; SECONDARY; RANIBIZUMAB;
D O I
10.1111/j.1755-3768.2008.01218.x
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Photodynamic therapy (PDT) with verteporfin has been used less comprehensively in the treatment of exudative age-related macular degeneration (AMD), and specifically of choroidal neovascularization (CNV), since the advent of antiangiogenic therapies. Recently, there has been a renewed interest in PDT as an adjunct to these and other agents in the treatment of neovascular AMD. In light of this new development and the European Medicines Evaluation Agency's (EMEA) recent labelling decision to rescind approval for the use of PDT in occult CNV lesions, the present systematic review was undertaken to revisit the evidence supporting its clinical application. Photodynamic therapy provided the first pharmacological treatment for patients suffering from subfoveal CNV, the major cause of severe vision loss in AMD. Key clinical trials evaluating efficacy and safety have examined patients with all lesion subtypes, with the primary labelled indication (i.e. lesions containing a classic component of >= 50% ) deriving from the results of the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study. The subsequent TAP Study Group post hoc categorization of lesions as predominantly classic is open to question, however, as it appears that the overall efficacy in this group only may have reflected the especially strong response in 100% classic lesions. Based on a subgroup analysis of the Verteporfin in Photodynamic Therapy Study, the indication for PDT subsequently was expanded in some jurisdictions, including that of the EMEA, to include occult lesions with no classic component. However, the subsequent Visudyne in Occult Study found no benefit in 100% occult lesions, resulting in the EMEA rescinding its approval for this indication.
引用
收藏
页码:118 / 132
页数:15
相关论文
共 93 条
[1]   Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies [J].
Ambati, J ;
Ambati, BK ;
Yoo, SH ;
Ianchulev, S ;
Adamis, AP .
SURVEY OF OPHTHALMOLOGY, 2003, 48 (03) :257-293
[2]   Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration [J].
Arias, L ;
Pujol, O ;
Berniell, J ;
Rubio, M ;
Roca, G ;
Castillo, L ;
Acebes, E .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (03) :312-315
[3]  
Arnold J, 2001, AM J OPHTHALMOL, V131, P541
[4]   Verteporfin therapy and triamcinolone acetonide: Convergent modes of action for treatment of neovascular age-related macular degeneration [J].
Augustin, A. J. ;
Schmidt-Erfurth, U. .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2006, 16 (06) :824-834
[5]   Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration [J].
Augustin, AJ ;
Schmidt-Erfurth, U .
OPHTHALMOLOGY, 2006, 113 (01) :14-22
[6]   Triple therapy for choroidal neovascularization due to agerelated macular degeneration - Verteporfin PDT, bevacimmab, and dexamethasone [J].
Augustin, Albert J. ;
Puls, Stephan ;
Offermann, Indre .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (02) :133-140
[7]   Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration [J].
Axer-Siegel, R ;
Ehrlich, R ;
Rosenblatt, I ;
Kramer, M ;
Priel, E ;
Yassur, Y ;
Weinberger, D .
ARCHIVES OF OPHTHALMOLOGY, 2004, 122 (04) :453-459
[8]   Photodynamic therapy for age-related macular degeneration in a clinical setting: Visual results and angiographic patterns [J].
Axer-Siegel, R ;
Ehrlich, R ;
Yassur, Y ;
Rosenblatt, I ;
Kramer, M ;
Priel, E ;
Benjamini, Y ;
Weinberger, D .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (02) :258-264
[9]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[10]  
Benjamin LE, 1998, DEVELOPMENT, V125, P1591